

FOR IMMEDIATE RELEASE**Contacts:**

Sondra Newman, Pure Communications
(617) 877-5687

Achaogen to Present at Cowen and Company 29th Annual Health Care Conference

SAN FRANCISCO, CA, March 10, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that J. Kevin Judice, Ph.D., chief executive officer and chief scientific officer, is scheduled to present at the Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17, 2009 at 3:00 p.m. EDT at the Boston Marriott Copley Place in Boston, Mass.

About Achaogen

Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science to develop drugs today that will combat tomorrow's resistant pathogens. This scientific strategy represents a novel approach to addressing the global bacterial resistance crisis.

Achaogen is creating new medicines that anticipate the next wave of anti-bacterial infections, including agents for the underserved Gram-negative infectious disease market and methicillin-resistant *Staphylococcus aureus* (MRSA). Achaogen's most advanced compound, ACHN-490, one of the company's next generation aminoglycosides known as neoglycosides, entered the clinic in January 2009, and the company has several other innovative small molecule antibacterial programs nearing clinical development. South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from NIH, the U.S. Department of Defense, the Wellcome Trust and other sources. Venture capital investors include 5 AM Ventures, ARCH Venture Partners and Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company's website at www.achaogen.com.

###